VTVT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
vTv Therapeutics Inc (VTVT) is not a strong buy at the moment for a beginner investor with a long-term focus. While the stock has potential due to its promising drug development pipeline and positive analyst ratings, the lack of financial growth, negative technical indicators, and absence of strong trading signals suggest waiting for more favorable conditions before investing.
The MACD is negatively expanding (-0.197), indicating bearish momentum. RSI is at 34.075, which is neutral but leaning towards oversold territory. Moving averages are converging, showing no clear trend. The stock is trading below the pivot level (37.698), with support at 34.94 and resistance at 40.456. Overall, the technical indicators suggest a weak or uncertain trend.
Analysts have consistently raised price targets, with the latest targets ranging from $44 to $55, citing the potential of cadisegliatin for type 1 diabetes.
The drug holds Breakthrough Therapy Designation, which is a significant regulatory advantage.
Financial performance is weak, with revenue dropping to zero and gross margin also at zero in Q4
Technical indicators are bearish, and the stock has a 60% chance to decline in the short term.
No recent news or significant trading trends from insiders or hedge funds.
In Q4 2025, revenue dropped to zero (-100% YoY), gross margin also fell to zero (-100% YoY), and net income improved to -$7.14M (+96.42% YoY). EPS increased slightly to -0.57 (+3.64% YoY). Overall, the financials indicate poor revenue performance but slight improvement in net income and EPS.
Analysts are bullish on the stock, with recent ratings from Evercore ISI, Alliance Global, and BTIG all maintaining Buy or Outperform ratings. Price targets have been raised to $44, $49, and $55, reflecting optimism about the company's drug pipeline and its potential impact on type 1 diabetes treatment.
